Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV)- Clinical Trial
NCT06367699 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29
Last updated 2025-07-15
Summary
The objective of this study is to assess the use of and satisfaction with the ECA-HPV intervention over a 16-month period, its ability to increase HPV vaccination, and the comparative effectiveness of clinic notification and adolescent ECA components on these factors.
Conditions
Interventions
- BEHAVIORAL
-
Usual Care
Parent/guardian and adolescent participants will not receive the ECA-HPV system intervention. A survey will be given via REDCap to the parent/guardian and adolescent participants at baseline, after the first well child clinic visit, and after the second well child clinic visit to assess self-reported vaccination attitudes and behaviors. Adolescent participants will receive usual care.
- BEHAVIORAL
-
ECA-HPV App with Clinic Notification and Adolescent Functions Disabled
Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors. Parent/guardian participants will also be asked questions about the ECA-HPV app. The clinic notification and adolescent functions of the complete ECA-HPV app are disabled. Adolescent participants will receive usual care.
- BEHAVIORAL
-
ECA-HPV App with Clinic Notification Function Enabled
Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors. Parent/guardian participants will also be asked questions about the ECA-HPV app and the clinic notification feature. The clinic notification is enabled on the parent/guardian ECA-HPV app, however, the adolescent does not have access to the adolescent ECA-HPV app. Adolescent participants will receive usual care.
- BEHAVIORAL
-
ECA-HPV App with Adolescent Function Enabled
Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors as well as ECA-HPV app use and satisfaction. The adolescent function is enabled, however, the clinic notification function is disabled. Thus, the ECA-HPV system app will have an adolescent-facing feature for adolescent participants to engage with the agent. Adolescent participants will receive usual care and will be able to engage with the adolescent version of the ECA-HPV app throughout the duration of the study.
- BEHAVIORAL
-
ECA-HPV App with Clinic Notification and Adolescent Functions Enabled
Parent/guardian participants will interact with the complete ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given to parent/guardian participants via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/ guardian and adolescent to assess self-reported vaccination attitudes and behaviors as well as ECA-HPV app use and satisfaction and questions about the clinic notification feature. The complete ECA-HPV app includes the parent version and adolescent versions of the ECA-HPV app. Both versions have the clinic notification feature enabled. Adolescent participants will receive usual care and can engage with the adolescent version of the ECA-HPV app throughout the study.
Sponsors & Collaborators
-
Boston Medical Center
collaborator OTHER -
Northeastern University
collaborator OTHER -
Tufts Medical Center
lead OTHER
Principal Investigators
-
Michael Paasche-Orlow, MD, MPH · Tufts Medical Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 8 Years
- Max Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-11-13
- Primary Completion
- 2025-04-01
- Completion
- 2025-04-01
Countries
- United States
Study Locations
More Related Trials
-
A Pilot Study Comparing the Effectiveness of Campus Intervention to Increase HPV Vaccine Rate Among College Aged Men
NCT02508701 ·Status: TERMINATED ·Phase: NA
-
PCOM2 - The Physician Communication Intervention, Version 2.0
NCT05336240 ·Status: RECRUITING ·Phase: NA
-
The STOP-HPV Scale Up Study
NCT06831383 ·Status: RECRUITING ·Phase: NA
-
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
NCT02546752 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
HPV Vaccine Integrated Service Implementation Research in Ethiopia
NCT06667323 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Multilevel Approach to Increasing HPV Vaccine Initiation Among Adolescents - Part 3
NCT04208269 ·Status: COMPLETED ·Phase: NA
-
Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers
NCT01087164 ·Status: UNKNOWN ·Phase: NA
-
Trial of a Social Marketing Campaign to Increase HPV Vaccination Among Mexican American Children
NCT02697396 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response
NCT03296397 ·Status: UNKNOWN ·Phase: PHASE3
-
txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men
NCT02994108 ·Status: COMPLETED ·Phase: NA
-
Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
NCT02710851 ·Status: UNKNOWN ·Phase: PHASE2
-
"Facts Tell… and With Stories Sell?" Combining Viewer-tailored Personal Human Papillomavirus (HPV) Narrative Video With HPV Vaccine Information Video to Improve HPV Vaccine Uptake
NCT06587243 ·Status: RECRUITING ·Phase: NA
-
Multi-level School-based Intervention to Improve HPV Vaccine Uptake and Completion in South Africa
NCT05919901 ·Status: SUSPENDED ·Phase: NA
-
AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections
NCT01654822 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL
NCT03911076 ·Status: TERMINATED ·Phase: PHASE2
-
Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis
NCT00829608 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)
NCT05677360 ·Status: SUSPENDED ·Phase: NA
-
Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama
NCT04604743 ·Status: WITHDRAWN ·Phase: NA
-
Parent-son-provider Decision-making About HPV Vaccination
NCT01284374 ·Status: COMPLETED
-
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
NCT06756269 ·Status: RECRUITING ·Phase: PHASE2
-
HPV Vaccine Hesitancy Among Indiana Youth With Cancer and Blood Diseases
NCT04667702 ·Status: COMPLETED
-
HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts
NCT02551887 ·Status: COMPLETED ·Phase: NA
-
Schoolbased HPV-counselling and -Vaccination
NCT05681169 ·Status: COMPLETED ·Phase: NA
-
Carrageenan-Containing Gel in Reducing the Rate of HPV Infection in Healthy Participants
NCT02382419 ·Status: WITHDRAWN ·Phase: PHASE2
-
Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination
NCT02897232 ·Status: COMPLETED